NeoGenomics (NEO) Stock Drops After 2026 Outlook Misses Expectations - News and Statistics

NeoGenomics (NEO) stock declined over 10% after its 2026 financial forecast, including adjusted earnings per share and adjusted EBITDA, fell short of analyst expectations, overshadowing strong fourth-quarter revenue growth. The company reported a net loss of $108 million for full-year 2025, a 37% increase, and its stock has been highly volatile, down 13% since the start of 2026. This performance underscores the market’s negative reaction to the weaker outlook despite positive quarterly revenue figures.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)